LOS ANGELES CAPITAL MANAGEMENT LLC
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 1177206
LOS ANGELES, CA
Position in APLS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$0
+$0 QoQ
Shares Held
85,913
-91.0% QoQ
Ownership
0.067%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2020
8 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
729,635 | $219,642,024 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,938,035 | $151,689,999 | |
| 3 | CAI |
Caris Life Sciences, Inc.
|
3,958,531 | $70,541,022 | |
| 4 | INCY |
Incyte Corp
|
578,986 | $65,633,852 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130,802 | $64,973,277 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,159,457 | $63,086,055 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
98,585 | $61,471,690 | |
| 8 | RPRX |
Royalty Pharma plc
|
877,674 | $49,211,181 |
All Filings in APLS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 85,913 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | — | 951,716 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | — | 620,790 | Shares | Sole | 2025-10-20 | |
| 2023-06-30 | — | 3,701 | Shares | Sole | 2023-08-03 | |
| 2022-09-30 | — | 4,314 | Shares | Sole | 2022-11-02 | |
| 2021-03-31 | — | 13,611 | Shares | Sole | 2021-05-05 | |
| 2020-12-31 | — | 8,805 | Shares | Sole | 2021-03-10 | |
| 2020-09-30 | — | 8,440 | Shares | Sole | 2020-11-02 | |
| No filing history on record for this holder in this stock. | ||||||